PPT-A phase 2 study with cabozantinib

in collecting duct carcinoma Bellini Giuseppe Procopio On the basis of preliminary promising data and due to its highspectrum biological activity against multiple and nonredundant oncogenic . PHASE 3 NON - ABULATORY STUDY What is “ CHERISH ?” CHERISH is a multi - compound, ISIS - SMN Rx , in children Spinal Muscular Atrophy (SMA). The study is a double - blind, randomized Global Investment Conference . September 2011. Forward-Looking Statements. This presentation contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, outlook, milestones, the success of Arno’s product development, potential advantages of Arno’s product candidates, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of our product candidates, our ability to finance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Arno is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. . Nick . Pavlakis. , MBBS, . MMed. (. Clin. Epi. ), . PhD. Royal North Shore Hospital. Sydney University. Outline. Aims of a Phase II study. Design aspects. Disease/population selection. Endpoint selection. Christopher . Jennison. , University of Bath. Robert A. Beckman, Daiichi Sankyo Pharmaceutical Development and University of California at San Francisco. Agenda. TOPIC 1: Where do subgroups come from? Empirical data or basic science? How does this vary as a function of developmental stage? . Weill Cornell Medicine. New York, New York. Investigational . Antiretroviral Drugs. FORMATTED. : . 01-13-17. New York, New York: February 24, 2017 . Learning Objectives. After attending this presentation. May 22, 2013. 2.  . Evaluating Uncertainty . Feedback from stakeholders and the Independent Scientific Panel (ISP) stressed that the understanding and evaluation of uncertainty is important in the prioritization. BRCA. -Mutated Breast Cancer. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Weill Cornell Medicine. New York, New York. Investigational . Antiretroviral Drugs. FORMATTED. : . 01-13-17. New York, New York: February 24, 2017 . Learning Objectives. After attending this presentation. Part 2. Resident and Fellows Lecture Series. A. pril 12, 2016. Elizabeth Garrett-Mayer, . PhD. Hollings Cancer . Center. . Current State of Phase II. Lots of changes in the past several years. Phase I . , . prodrug. of . temsavir. . (attachment inhibitor). AI438011 Study. TAF (TFV . prodrug. ). Study 292-0102. Study 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). MK1439007 Study. . Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, Yang H, Gee M, Zhu J, Laurenza A. Perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from Phase III, extension study 307. Ublituximab. , a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (. mAb. ), in Patients with Relapsing Forms of Multiple Sclerosis (RMS). Novel Glycoengineered Anti-CD20 . mAb. Unique protein sequence. A. ccelerated, . D. ose escalated, . S. equential . C. hemo-r. a. diotherapy . in . N. on-Small Cell Lung Cancer. Rationale:. Lung cancer. is the most common cause of cancer mortality in the UK, and . C. areers . and. A. cademic. L. iaison . C. ommittee . Inspiring school students to study statistics at our event,. “Maths meets Medicine”. An enthusiastic group of volunteers from a range of companies from across the industry.